Trial Profile
A Randomized, Open-Label Study of the Effect of Replacing CNI With Sirolimus in a Standard Care Regimen of CNI, CellCept, and Steroids on Renal Function in Heart Transplant Patients
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Sirolimus (Primary) ; Calcineurin inhibitors
- Indications Heart transplant rejection
- Focus Therapeutic Use
- Acronyms STN
- Sponsors Roche
- 27 Jul 2020 This trial is completed in UK (Global End Date: 01 Jun 2006), according to European Clinical Trials Database record.
- 25 Apr 2007 Results have been reported.
- 04 Sep 2006 Status change